Nyxoah logo

Nyxoah(NASDAQ) NYXH

Market Cap$135.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-94%
5 Year-95%
1 Year-73%
1 Month-11%
$1.34
-3.26%
-0.05Today
After hours$1.34+$0.01 (+0.38%)
Nyxoah last closing stock price
MetricPriceDate
Last closeUSD 1.332026-10-01
Nyxoah stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.72%USD 1.272026-09-24
1 month-10.74%USD 1.492026-09-01
3 month-22.67%USD 1.722026-07-02
Year to date-71.09%USD 4.602025-12-31
1 year-73.08%USD 4.942025-10-01
3 year-79.97%USD 6.642023-10-02
5 year-95.41%USD 29.002021-10-01
Since inception-94.25%USD 24.002021-04-28

Nyxoah Financials at a Glance

Market Cap

$135.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€22.65M

Net Income (TTM)

-€98.48M

EPS (TTM)

-$2.52

P/E Ratio

-0.53

Dividend

$0.00

Beta (Volatility)

0.73 (Low)

Price

$1.34

Volume

120,794.779

Open

$1.38

Previous Close

$1.33

Daily Range

$1.31 - $1.38

52-Week Range

$1.26 - $6.87

Estimated Earnings Date

Nov 5, 2026

NYXH News

featured-earnings-leadership-highlights.png

Nyxoah Q2 Revenue Jumps 74 Percent

Motley Fool Markets TeamAug 18, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nyxoah

Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative solutions for obstructive sleep apnea (OSA). The company's flagship product, the Genio system, offers a minimally invasive hypoglossal neurostimulation therapy designed for patients with moderate to severe OSA.

Products and Services
  • Genio system: A CE-Marked neurostimulation therapy for OSA
  • Patient-centric approach to treatment and care
  • Focus on minimally invasive medical technologies
Growth Outlook
  • Significant market potential in the OSA treatment sector
  • Increasing awareness and diagnosis of sleep apnea conditions
  • Expansion plans into new markets and regions
Financial Highlights
  • Q2 2026 revenue of €7.68 million, up from €7.36 million in Q1 2026
  • Gross profit margin improved to 59.7% in Q2 2026
  • Cash and cash equivalents reached €64.12 million as of June 30, 2026
Nyxoah S.A. has positioned itself as a key player in the medical technology industry, particularly in the treatment of obstructive sleep apnea. The Genio system represents a significant advancement in patient care, offering a less invasive option compared to traditional therapies. The company is well-placed to capitalize on the growing awareness and diagnosis of sleep apnea, which is expected to drive demand for its innovative solutions. Recent financial performance indicates a positive trend, with a notable increase in revenue and an improved gross profit margin. The substantial cash reserves provide a solid foundation for future growth initiatives and market expansion. As Nyxoah continues to innovate and expand its reach, it remains an intriguing option for investors interested in the healthcare sector.
AI Generated • Sep 24, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

153.7

CEO

Olivier Taelman, EMBA

Website

www.nyxoah.com

Headquarters

Mont-Saint-Guibert, WA 1435, BE

NYXH Financials

Key Financial Metrics (TTM)

Gross Margin

51.31%

Operating Margin

-383.05%

Net Income Margin

-434.72%

Return on Equity

-179.71%

Return on Capital

-90.97%

Return on Assets

-58.46%

Earnings Yield

-1.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$135.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

101.84M

Volume

120.79K

Avg. Volume

295.42K

Financials (TTM)

Gross Profit

€11.62M

Operating Income

-€86.77M

EBITDA

-€77.27M

Operating Cash Flow

-€71.81M

Capital Expenditure

-€2.05M

Free Cash Flow

-€73.86M

Cash & ST Invst.

€97.79M

Total Debt

€52.57M

Nyxoah Performance Analysis

Nyxoah annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,241,205221.9%
20232023-12-31EUR 4,700,69145.0%
20242024-12-31EUR 4,890,3244.0%
20252025-12-31EUR 11,308,351131.2%
Nyxoah sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3047.2%
Q42025-12-31186.2%
Q12026-03-3130.4%
Q22026-06-304.3%
Nyxoah annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.27-7.4%
20232023-12-31EUR -1.6731.4%
20242024-12-31EUR -1.9617.2%
20252025-12-31EUR -2.6736.3%
Nyxoah sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-14.5%
Q42025-12-316.3%
Q12026-03-3137.3%
Q22026-06-30-56.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€7.68M

+472.8%

Gross Profit

€4.58M

+439.3%

Gross Margin

59.73%

N/A

Market Cap

$135.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$879.53K

N/A

Employees

154

N/A

Net Income

-€32.96M

-60.0%

EBITDA

-€19.41M

-0.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€97.79M

+127.5%

Total Debt

€52.57M

+166.8%

Accounts Receivable

€9.95M

+76.1%

Inventory

€3.71M

-30.5%

Long Term Debt

€28.88M

+57.1%

Short Term Debt

€23.69M

+1698.5%

Return on Assets

-58.46%

N/A

Return on Invested Capital

-71.60%

N/A

Free Cash Flow

-€17.86M

-3.3%

Operating Cash Flow

-€16.57M

+0.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KRMDKORU Medical Systems, Inc.
$3.02+3.07%
STIMNeuronetics, Inc.
$2.22-5.13%
TARAProtara Therapeutics, Inc.
$2.76-9.51%
UTMDUtah Medical Products, Inc.
$74.35+0.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About NYXH

What is the current price of Nyxoah?

Nyxoah is trading at $1.33 per share.

What is the 52-week range for Nyxoah?

Over the past 52 weeks, Nyxoah has traded between $1.26 and $6.87.

How much debt does Nyxoah have?

As of the most recent reporting period, Nyxoah reported total debt of €68.58M.

How much cash does Nyxoah have on hand?

Nyxoah reported €73.30M in cash and cash equivalents in its most recent financial results.

What is Nyxoah’s dividend yield?

Nyxoah does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services